Matthew L Smith
Affiliation: Cancer Research UK
- Mutation of CEBPA in familial acute myeloid leukemiaMatthew L Smith
Medical Oncology Unit, Cancer Research UK, Barts and the London School of Medicine and Dentistry, St Bartholomew s Hospital, West Smithfield, London
N Engl J Med 351:2403-7. 2004..All three patients are currently well, with no abnormalities in the bone marrow. CEBPA mutation is apparently the primary event in the development of AML in this family...
- Development of a human acute myeloid leukaemia screening panel and consequent identification of novel gene mutation in FLT3 and CCND3Matthew L Smith
Cancer Research UK Medical Oncology Unit, Charterhouse Square, Barts and the London School of Medicine and Dentistry, London
Br J Haematol 128:318-23. 2005..A 51-bp deletion was detected in CCND3 in a patient with normal karyotype AML. This validated panel now provides an important tool to evaluate other candidate genes in the genesis of myeloid malignancy...
- Mutations of CEBPA in acute myeloid leukemia FAB types M1 and M2Jennifer Snaddon
Cancer Research UK Medical Oncology Unit, Charterhouse Square, St Bartholomew s Hospital, London, United Kingdom
Genes Chromosomes Cancer 37:72-8. 2003..In conclusion, mutation of CEBPA is a recurrent finding in AML and appears specific to the intermediate cytogenetic risk group patients...
- Development of a quantitative real-time polymerase chain reaction method for monitoring CEBPA mutations in normal karyotype acute myeloid leukaemiaLan-Lan Smith
Br J Haematol 133:103-5. 2006